|
시장보고서
상품코드
1546284
세계의 심전계(ECG) 시장 평가 : 유형별, 기술별, 리드 유형별, 최종사용자별, 지역별, 기회 및 예측(2017-2031년)Electrocardiograph (ECG) Market Assessment, By Type, By Technology, By Lead Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
||||||
세계 심전계(ECG) 시장 규모는 2023년 84억 190만 달러에서 2031년 152억 3,169만 달러에 달할 것으로 예상되며, 예측 기간인 2024년부터 2031년까지 연평균 7.72% 성장할 것으로 예상됩니다. 시장은 심장 질환의 증가로 인해 꾸준히 성장하고 있으며, 앞으로도 큰 성장이 예상됩니다.
심전계는 심박수를 기록하고 심혈관질환의 가능성을 분석하는 데 사용되는 기기이자 기술입니다. 심혈관질환의 부담이 증가함에 따라 심전도 시술 및 새로운 기기에 대한 수요도 증가하고 있으며, 심전도 기기 시장은 설계 및 기능의 기술적 진보, AI 및 기기 학습의 통합, 심전도 기록에 사용되는 웨어러블 기기의 성장 추세 등의 요인에 영향을 받아 성장할 것으로 예상됩니다. 충분한 수의 의료기기를 구비하고 의료 인프라를 강화하려는 정부의 노력은 시장 성장을 촉진하고 있습니다. 또한, ECG 기기에 기술을 통합하는 투자 증가와 신생 스타트업이 시장 성장을 촉진하고 있습니다.
예를 들어, 2024년 4월 벵갈루루의 헬스테크 스타트업인 Tricog Health India Pvt Ltd.는 OMRON Healthcare India Pvt Ltd. 라운드에서 850만 달러의 투자를 유치했습니다. 이 회사는 AI를 사용하여 ECG/EKG 및 ECHO 스캔을 분석하여 심장 이상을 진단하고 있으며, 이번 자금 조달은 AI를 활용한 심장 관리 솔루션의 추가 개발로 이어질 것입니다. 그러나 여러 촉진요인이 있음에도 불구하고, 수많은 현지 기업의 시장 포화, 국가마다 다른 엄격한 규제 절차 등의 과제가 시장 성장에 큰 걸림돌로 작용하고 있습니다.
심혈관질환의 유병률 증가
세계적으로 심혈관질환의 부담이 증가함에 따라 이러한 질환을 조기에 발견하고 관리할 수 있는 심전도 기기 및 관련 진단 기술에 대한 수요 증가와 채택이 증가하고 있습니다. 심혈관질환은 주로 심전도 기술로 진단되기 때문에 심혈관질환의 부담 증가는 심전도 장비 및 서비스에 대한 수요 증가로 이어지며, 미국심장협회(American Heart Association), 영국심장재단(British Heart Foundation), 세계보건기구(WHO) 등 심혈관 건강을 위해 활동하는 다양한 단체들은 심혈관질환의 상당한 증가를 지속적으로 보고하고 있습니다. 예를 들어, 2024년 6월 미국심장협회(American Heart Association)의 두 가지 새로운 회장 권고안에 따르면, 미국 인구의 61% 이상인 1억 8,400만 명 이상이 심혈관질환(CVD)에 걸릴 가능성이 있으며, 2050년까지 CVD 관련 총 비용이 3배로 증가할 것으로 예측했습니다. 3배인 1조 8,000억 달러에 달할 것으로 예측됩니다.
기술의 발전이 시장 성장을 촉진
다른 의료 기술 분야와 마찬가지로 심전도 장비도 여러 가지 기술적 진보를 보이고 있습니다. 최근 기술 발전에는 웨어러블 심전도 기기(미국 FDA 승인을 받은 Apple Watch Series 4 등), AI 지원 심전도 해석, 휴대용 심전도 모니터, 비접촉식 모니터링 시스템, 클라우드 기반 시스템, 원격의료와의 통합 등이 포함됩니다. 이러한 발전은 심장 질환의 진단 정확도를 높이고 데이터 수집 및 분석의 효율성을 높이는 것을 목표로 하며, ECG에 AI를 통합하는 것은 극적인 개선을 가져와 환자가 ECG 서비스에 쉽게 접근할 수 있게 하고, 이후 시장 확대로 이어질 것으로 예상됩니다. 예를 들어, 2024년 5월 OMRON Healthcare India Pvt Ltd는 AliveCor India(AliveCor의 자회사)와의 제휴를 발표했습니다. 이 제휴를 통해 오므론은 혈압 모니터링 제품 외에도 AI 기반 휴대용 휴대용 심전도 기술을 제공하게 됩니다. 이를 통해 심방세동을 포함한 다양한 부정맥을 감지하고 심혈관질환을 조기에 발견하고 관리할 수 있는 기기를 개발할 수 있게 됩니다. 이번 계약은 특히 고혈압과 심전도 모니터링의 격차가 큰 인도와 같은 국가에서 심혈관 건강에 대한 인식을 높이고 발병을 예방하는 것을 목표로 하고 있습니다.
이 보고서는 세계 심전계(ECG) 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황 및 전망 등의 정보를 전해드립니다.
Global electrocardiograph (ECG) market is projected to witness a CAGR of 7.72% during the forecast period 2024-2031, growing from USD 8401.90 million in 2023 to USD 15231.69 million in 2031. The market for ECG devices is rising consistently due to increasing cardiac diseases and is anticipated to keep growing at a significant rate.
An electrocardiograph is a device and technique used to record the heartbeat and analyze any possible cardiovascular disorder. As the burden of cardiovascular diseases increases, the demand for more ECG procedures and new devices subsequently rises. The market for ECG devices is anticipated to thrive under the influence of factors like technical advancements in design and functions, integration of artificial intelligence (AI) and machine learning, the growing trend of wearable devices for recording ECG, etc. The government initiatives to strengthen the healthcare infrastructure by establishing an adequate number of medical devices drive the growth in the market. Additionally, rising investments and emerging startups integrating technology in ECG devices are boosting the market growth.
For instance, in April 2024, Tricog Health India Pvt Ltd., a Bengaluru-based health tech startup, raised USD 8.5 million in a Series B2 funding round from investors including OMRON Healthcare India Pvt Ltd and Sony Innovation Fund. The company uses AI to analyze ECG/EKG and ECHO scans to diagnose heart anomalies, and the new funding will help it further develop its AI-powered cardiac care solutions. However, despite several driving forces, challenges like saturation in the market due to the large number of local players, and stringent regulatory procedures varying from country to country pose significant hindrances to market growth.
Rising Prevalence of Cardiovascular Diseases
The rising burden of cardiovascular diseases globally is a key factor fueling increased demand and adoption of ECG machines and related diagnostic technologies to enable earlier detection and management of these conditions. Cardiovascular diseases are mainly diagnosed with ECG technology, which implies that an increase in cardiovascular disease burden will enhance the demand for ECG devices and services. Various associations working for cardiovascular health, such as the American Heart Association, the British Heart Foundation, and WHO, are consistently reporting a significant rise in cardiac diseases. For instance, in June 2024, as per the projections reported in two new American Heart Association presidential advisories, more than 184 million people, exceeding 61% of the U.S. population, are likely to have some type of cardiovascular disease (CVD) and total CVD-related costs are expected to triple to USD 1.8 trillion by 2050.
Technological Advancements Drive Market Growth
Aligning with other domains of medical technology, ECG devices are also undergoing several technical advancements. Some of the recent technical advancements include wearable ECG devices (for example, U.S. FDA-approved Apple Watch Series 4), AI-assisted ECG interpretation, portable ECG monitors, contactless monitoring systems, cloud-based systems, integration with telemedicine, and many more. These advances aim to improve accuracy in the diagnosis of heart conditions and enhance the efficiency of data collection and analysis. AI integration in ECG is anticipated to result in drastic improvements, leading to easy patient access to ECG services and subsequent market expansion. For instance, in May 2024, OMRON Healthcare India Pvt Ltd announced a collaboration with AliveCor India (a subsidiary of AliveCor, Inc.). Through this partnership, OMRON will now offer AI-based handheld portable ECG technology in addition to its blood pressure monitoring products. The collaboration will result in devices that can detect various heart arrhythmias, including atrial fibrillation, and provide early cardiovascular disease detection and management. The deal aims to enhance cardiovascular health awareness and prevent incidents, especially in a country like India, where hypertension and ECG monitoring gaps are significant.
Devices Segment Dominates the Global (ECG) Market
ECG device installations are increasing with the expanding healthcare infrastructure. With the rising burden of cardiac diseases and subsequent demand for more ECG procedures and devices, the ECG device segment is anticipated to cover a major market share. Technical advancements and device upgrades in diagnostic centers and hospitals further catalyze the increasing market share of the devices segment. For example, in January 2024, Wellysis Corp. launched its revolutionary electrocardiogram (ECG) monitoring solution, 'S-Patch,' into the lucrative United States and Indian markets. The company has secured a strategic supply agreement with a leading provider of ECG services in the United States, initially deploying 1,000 devices across Texas, Arizona, and Louisiana, with a two-year supply commitment. Additionally, Wellysis has partnered with Turtle Shell Technologies Private Limited (Dozee), a prominent bed monitoring solutions provider in India, to integrate and supply 50,000 S-Patch devices to hospital beds starting in January.
North America Dominates Electrocardiograph (ECG) Market Share
North America is anticipated to dominate the ECG market. North America, particularly the United States, has a significant demand for ECG devices due to several key factors. The high prevalence of cardiovascular diseases, an aging population, and a well-developed healthcare infrastructure with robust reimbursement policies have all contributed to this demand. Sustained efforts by healthcare organizations like the U.S. FDA to raise awareness about heart health and product approvals are also driving the demand for these diagnostic and monitoring tools in North America. For instance, in June 2024, Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device, an AI-based algorithm designed to identify patients at increased risk of atrial fibrillation (AF). This innovative technology uses machine learning to analyze 12-lead electrocardiogram (ECG) recordings, helping clinicians detect signs of AF within the next 12 months. The device is intended for use on resting ECG recordings from patients aged 65 and older without a known history of AF.
Future Market Scenario (2024-2031F)
ECG technology plays a pivotal role in the cardiology domain, and with growing advancements, the machinery for recording ECG has changed drastically in recent years. The evolving trend of wearable devices has greatly impacted ECG monitoring as well. Nowadays, several smartwatches and other kinds of wearable devices are available in the market that can easily record patients' ECGs. This is anticipated to revolutionize the ECG market in upcoming years. Market players are also actively developing wearable devices to cater to the rising demand. For instance, in September 2023, iRhythm Technologies, Inc. launched its next-generation Zio monitor. This prescription-only ECG monitoring device is part of the company's Zio long-term continuous monitoring (LTCM) service. The new Zio monitor is 23% thinner, 62% lighter, and 72% smaller than its predecessor, enhancing patient comfort and adherence. It features a waterproof design and requires no device or adhesive manipulation during the 14-day wear period.
Key Players Landscape and Outlook
GE HealthCare Technologies, Inc., Koninklijke Philips N.V., Hill-Rom Holdings, Inc., NIHON KOHDEN CORPORATION, Fukuda Denshi Co Ltd, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Schiller AG, Spacelabs Healthcare, Inc., BPL MEDICAL TECHNOLOGIES PRIVATE LIMITED, Allengers Medical Systems Ltd are some of the leading players in the ECG market. The market witnessed some substantial market deals like mergers and collaborations to expand the market share of key players.
In February 2024, Thyrocare Technologies Ltd., a leading diagnostic service provider, acquired Chennai-based Think Health Diagnostics Pvt Ltd to expand its presence in the pre-policy medical check-up segment for the insurance market by offering both blood tests and ECGs as a one-stop solution, leveraging Think Health's operational presence in 10 cities and Thyrocare's network of over 900 blood collection phlebotomists trained to provide ECGs at home, aiming to expand these services to more than 100 cities in the next year and deliver seamless healthcare directly to patient's doorsteps.
In May 2024, WearLinq, Inc. acquired AMI Cardiac Monitoring LLC, which is an independent diagnostic testing facility with over 33 years of expertise in ambulatory cardiac monitoring. This strategic acquisition will expand WearLinq's clinical services across all 50 U.S. states and provide more patients access to its FDA-cleared 6-lead wearable ECG monitor, the eWave. The combined capabilities of AMI's clinical expertise and WearLinq's advanced technology are expected to revolutionize the field of ambulatory cardiac monitoring, enabling more accurate diagnoses and improved patient outcomes.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.